Monitoring linezolid levels to improve treatment for drug-resistant tuberculosis
Official title: Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Funded at Albert Einstein College of Medicine · NIH-11095559 · Data updated 2026-11-12
This study is looking at how keeping track of the right amount of the drug linezolid can help people with rifampin-resistant tuberculosis and HIV feel better and have fewer side effects, by finding the best dose for their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $766,877 |
| NIH project number | 1R01AI184416-01A1 |
| Project ID | NIH-11095559 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who are diagnosed with rifampin-resistant tuberculosis and may also be living with HIV.
✕Less likely to help
Patients who do not have rifampin-resistant tuberculosis or are not on linezolid treatment may not benefit from this research.
What this research studies
This research investigates how monitoring the levels of the drug linezolid can enhance treatment outcomes for patients with rifampin-resistant tuberculosis, particularly those living with HIV. The study aims to identify optimal drug concentrations to minimize side effects while maximizing effectiveness, as high levels of linezolid can lead to serious toxicities. By conducting a pragmatic randomized controlled trial, the researchers will assess the impact of tailored dosing on patient health and treatment success.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that enhance survival rates and reduce side effects for patients with drug-resistant tuberculosis.
How similar studies have gone: Previous research has shown that monitoring drug levels can improve treatment outcomes in other conditions, suggesting a promising approach for this study.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Brust, James C M — Albert Einstein College of Medicine
- Study coordinator: Brust, James C M
Related research
Other NIH-funded projects on the same topics.
-
Shorter, rifamycin-free TB treatment using BCZD for drug-susceptible TB
A 12-week, AI-informed drug combination (bedaquiline, clofazimine, pyrazinamide, and delamanid) is being tested against the standard 26-week therapy for adults with drug-susceptible TB to see if it can cure faster with fewer side effects.
-
Shorter TB treatment using four drugs for drug-susceptible TB
A 12-week, AI-informed drug regimen (bedaquiline, clofazimine, pyrazinamide, delamanid) is being tested against standard therapy for drug-susceptible TB to see if it works faster and safely across adults in Haiti and South Africa.
-
Personalized linezolid dosing for rifampin-resistant tuberculosis
This work compares standard linezolid dosing to dosing adjusted using blood tests to help adults with rifampin-resistant tuberculosis, including people living with HIV, get effective treatment while reducing harmful side effects.
-
Ultra-short, rifamycin-free treatment for drug-susceptible tuberculosis
This compares a four-drug, rifamycin-free, very short TB treatment to the usual longer therapy for adults with drug-susceptible tuberculosis, including people taking HIV medicines.
-
Ultra-short rifamycin-free TB treatment using bedaquiline, clofazimine, pyrazinamide and delamanid
This trial sees if a four-drug, rifamycin-free regimen can cure drug-susceptible tuberculosis much faster than standard therapy for adults, including people with HIV.
-
Ultra-short bedaquiline-based regimen for drug-susceptible TB
A 12-week, AI-guided drug combination trial tests a shorter, rifamycin-free treatment for adults with drug-susceptible TB, aiming to cure faster with fewer drug interactions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.